Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Selventa Developing Powerful New Class of Multi-omic Based Diagnostic Test

Published: Friday, February 01, 2013
Last Updated: Thursday, February 07, 2013
Bookmark and Share
This powerful new class of diagnostic test will accelerate the implementation of personalized healthcare.

Systems Diagnostics, or SysDx™, will be a novel diagnostic tests that can consist of “multi-omic” biomarkers selected through a rigorous Big Data analysis of a patient’s biological profile including genomic, epigenomic, transcriptomic, proteomic, metabolomic and electronic medial record information. From this analysis, Selventa will generate a differentiated and clinically-relevant report that physicians and patients can use to improve therapy selection.

“SysDx testing is a much needed progression from ‘single-omic’ tests that today are largely limited to the analyses of genetic aberrations in a patients disease,” said Dr. David de Graaf, President and CEO, Selventa. “Because the molecular drivers of disease are manifested across thousands of interrelated biochemical pathways, it is vital that a diagnostic be able to test for a more comprehensive set of disease-relevant biomarkers. SysDx testing promises to capture a more detailed profile of a patient’s disease leading to more informed healthcare decisions.”

Selventa is currently focusing its SysDx development in autoimmune and cancer. These complex multi-factorial diseases require more than genetic information alone to gain an effective diagnosis that can guide treatment. 

Dr. de Graaf added, “SysDx is a natural outgrowth of our successful 10-yr heritage as a leader in systems biology and biomarker identification for pharma and biotech.  Our ‘Big Data’ analytics and algorithms uniquely integrate, process and analyze different molecular information from thousands of patients to identify biomarkers. This unique capability is the foundation for SysDx tests that will have stronger validation, higher reliability and provide superior predictive and prognostic capabilities.”

 Selventa has achieved proof of concept for multiple SysDx tests in:

• Rheumatoid Arthritis (RA)

• Inflammatory Bowel Disease (IBD)

o   Crohn’s disease
o   Ulcerative colitis

• Multiple cancers

Selventa’s lead product will be Clarify-RA, a SysDx test that will be able to predict which patients suffering from RA will not respond to the standard of care anti-TNF therapy.

 RA is a chronic, debilitating disease that affects an estimated 2 million people in the United States. It is also an expensive disease to treat, costing the healthcare system on average USD 20,000 per patient every year. In moderate to severe RA patients, only 40% of patients gain a clinically significant benefit from the anti-TNFs.

 Dr. de Graaf added, “A large unmet medical need is to identify early if a patient is a non-responder to the standard of care therapy in the care cycle. It is estimated that 50% of all prescribed drugs lack efficacy, or worse are dangerous to the patient. A SysDx that can identify non-responders to major classes of drugs will benefit the patient and also deliver tangible cost benefits to payers. Furthermore, this increased knowledge about patients will help pharmaceutical companies to re-position their drugs.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Selventa Strengthens Intellectual Property for SysDx™ Approach to Personalized Medicine
Patent is core to Selventa’s SysDx™ approach to mining and comparing biological data for predicting a patient’s response or non-response to a drug.
Thursday, May 09, 2013
David de Graaf Appointed as a Scientific Advisory Board Member for Swiss Institute of Bioinformatics
David de Graaf, Chief Executive Officer for Selventa™, has been appointed as a Scientific Advisory Board member for the SIB Swiss Institute of Bioinformatics.
Tuesday, August 16, 2011
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!